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Bourguiba, Monastir, TunisiaAbstractNoroviruses (NoVs) constitute a major cause of gastroenteritis in Tunisia. One hundred and fourteen matched saliva and stool samples were
collected from children (n = 114) suffering from acute gastroenteritis at the hospital of Monastir during the winter season 2011–2012. For 98
of 114 children, blood samples were collected for secretor genotyping. NoVs were associated with 36.8% (n = 42/114) of the gastroenteritis
cases. The GII.3 genotype was the most common (69% of all NoVs). For patients who were phenotyped (n = 114) for human blood group
antigens (HBGAs), the secretor and non-secretor phenotypes represented 79% and 21%, respectively. Of the NoV infections, 83% were
detected in all ABO groups. Five GII.3 isolates, one GII.1 isolate and one GII.7 isolate were detected in Lewis-positive non-secretors,
conﬁrmed by genotyping of the FUT2 gene. Even though our data showed that GII.3 NoVs could infect non-secretors, no binding was
observed with saliva and GII.3 baculovirus-expressed virus-like particles from the same symptomatic non-secretor individual. This
suggests that other factors might also participate in NoV attachment in children and newborns.
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E-mail: gael.belliot@u-bourgogne.frIntroductionEach year, millions of people suffer from acute gastroenteritis
(AGE) worldwide. Rotavirus and norovirus (NoV) are the main
causative agents of gastroenteritis in all age groups. Group A
rotavirus is the leading cause and human NoVs are the second
leading cause of AGE in children aged <5 years. NoVs belong to
one of the four genera constituting the Caliciviridae family, andMicrobiol Infect 2015; 21: 874.e1–874.e8
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.05.015are divided into six genogroups, but only genogroup (G)I, GII
and GIV infect humans. There are eight and 17 genotypes
within GI and GII, respectively, according to VP1 coding
sequence analysis [1]. Among NoVs, GII genotype 4 (GII.4) is
globally the most predominant, and can be classiﬁed into sub-
types or variants [2], which follow on one after the other as a
global epidemic strain every 2 or 3 years [3].
The human blood group antigens (HBGAs) are involved in
NoV attachment to intestinal cells [4]. Expression of the
HBGAs (A, B, H and Lewis antigens) in saliva and on the surface
of intestinal cells is driven by the FUT2 (A, B and H antigens) and
FUT3 (Lewis antigens) genes, which encode type 2 and type 3
fucosyltransferases, respectively [5]. Lewis antigen expression is
also partly dependent on the ABO phenotype, as the FUT3
enzyme elongates H type 1 antigen, which is controlled by the
active FUT2 enzyme. Approximately 20% of the Caucasianious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Ayouni et al. Norovirus and HBGA 874.e2population are homozygous for a recessive point mutation of
the FUT2 gene, which leads to the absence of A, B and H antigen
expression, also called the non-secretor phenotype. There is
also a Lewis-negative phenotype due to various mutations of
the FUT3 gene, as reviewed previously [6], but the percentage
of genotype and allele mutations varies considerably with
ethnicity [7,8].
Genetic differences may thus play a role in susceptibility to
NoV infection in humans, as non-secretor individuals are not
susceptible or are less susceptible than secretors to infection
[9]. Indeed, HBGA ligands participate in NoV attachment at the
surface of intestinal cells via amino acid residues that directly
interact with the sugar moiety [4,10,11]. NoV infection mainly
occurs in secretor individuals, among whom blood group O
individuals are more likely to be infected by any NoV genotype
[9,12–15]. NoV infection, mainly with GII.3 and GII.4, has also
been reported in non-secretors, although the number of
infected individuals was lower [12,13,16,17]. Nonetheless,
susceptibility to NoV infection seems to be much more com-
plex. Recent data have shown that adult non-secretor in-
dividuals infected with CagA Helicobacter pylori might become
more susceptible because of abnormal expression of fucosy-
lated motifs at the surface of intestinal cells, while it is absent
from saliva [18]. Additionally, it has been shown that enteric
bacteria from unﬁltered stools, such as H antigen-expressing
Enterobacter cloacae, promote in vitro infection of B-cells by
human NoV [19].
A recent epidemiological survey of children in the Monastir
region (Tunisia) allowed us to determine whether NoV paedi-
atric infections were linked to secretor status and HBGAs. The
observations regarding NoVs were further supported by the
analysis of saliva from patients and the use of baculovirus-
expressed synthetic particles from a strain that was isolated
during the study in a non-secretor patient.Materials and methodsStudy design
One hundred and fourteen individual stool and saliva samples
were collected from children aged <6 years who consulted
for AGE at the Children’s Hospital of Monastir (Tunisia)
from January 2011 to August 2012. At the onset of the
disease, blood samples were also collected from 98 of these
114 patients. The study was approved by the Ethics Com-
mittee of the Fattouma Bourguiba Public Hospital at Monastir
(Tunisia) (committee decision of 9 May 2013), and informed
consent was obtained from the parents of the 114 children.
Blood and saliva samples were taken in the presence of the
parents.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InNoV detection and typing
Viruses were screened for and characterized at the National
Reference Centre for Enteric Viruses in Dijon, France. For each
patient, 800 μL of a 10% stool suspension was prepared in
phosphate-buffered saline (PBS) before extraction of nucleic
acids with a Nuclisens Easy MAG system (bioMérieux, Marcy
l’Etoile, France), according to the manufacturer’s instructions.
RNA was eluted in a ﬁnal volume of 110 μL.
Clinical specimens were ﬁrst screened by real-time RT-PCR
with Taqman technology. Five microlitres of RNA was used for
the real-time RT-PCR assay, which was performed with an ABI
Prism 7500 sequence detection system (Life Technologies, Saint
Aubin, France), according to the manufacturer’s instructions.
For GI NoVs, the JJV1NF/JJV1R primer pair and JJV1P and
RING-1b probes were used [20]. For GII NoVs, the QNIF2d
and COG2R primers were combined with the QNIF2 probe as
described previously [21]. Samples giving Ct values of >40 were
considered to be negative. The samples that were positive by
real-time RT-PCR were then genotyped for the polymerase
region with the JV12/JV13 primer pair for the polymerase [22].
For the capsid region, the G1SKF/G1SKR and G2SKF/G2SKR
primer pairs were used for the ampliﬁcation of GI and GII
NoVs, respectively [23]. Following sequencing of the PCR
products, the NoV genotypes were determined by alignments
with reference sequences from GenBank by the use of MEGA5
software [24].
Cloning of the GII.3 isolate, and production and
puriﬁcation of baculovirus-expressed virus-like
particles (VLPs)
A GII.3 NoV isolate (SW4 strain) from a non-secretor Lewis-
positive individual from the study was further characterized and
cloned into a baculovirus system to produce VLPs for the saliva
binding assay. The FW1/RT5 (Table S1) primer pair was used to
amplify open reading frame (ORF)2, with the same PCR reagents
and ampliﬁcation conditions as described previously [25]. PCR
products were cloned into the pGEM-T easy vector to generate a
pGII.3-pGEM construct, whichwas later sequencedwith primers
FW1–FW5 and RT1–RT5 (Table S1). pGII.3-pGEM was used as
the template to amplify ORF2 with the forward primer 50-
GAAGATCTATGAAGATGGCGTCGAATGACGC-30, which
contains a BglII site at the 50 end, (underlined), and RT5 as the
reverse primer, which overlaps with ORF2 and ORF3 at the 30
and 50 ends, respectively. Ampliﬁed ORF2 with the BglII site was
gel-puriﬁed and cloned into pGEM-T easy. One positive clone
was digestedwith BglII andNotI and puriﬁed from gel before being
cloned into transfer vector pVL1392 (BD Bioscience, Le Pont de
Claix, France), which was entirely sequenced to determine the
presence of any inadvertent mutations. The recombinant bacu-
lovirus was obtained by co-transfection of the pVL vector and thefectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e1–874.e8
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manufacturer’s recommendations (BD Bioscience). Following
transfection, 20 clones were selected after plaque assay by ELISA
with an in-house rabbit polyclonal antibody raised against GII.3.
The recombinant baculovirus showing the highest optical density
by ELISA was selected, and was cloned a second time by plaque
assay. Thereafter, the inoculum of the selected recombinant
baculovirus was ampliﬁed and titrated by infecting Sf9 at a mul-
tiplicity of infection of 0.1. The Sf9-produced inoculum was then
used to infect Hi-5 cells (Life Technologies) at a multiplicity of
infection of 5 with serum-free Express Five medium (Life Tech-
nologies). The cells were incubated for 6 days at 27°C prior to
concentration and puriﬁcation of the recombinant VLPs from
infected cell lysates, as described previously [26,27].
Saliva typing for carbohydrates
Saliva samples were screened for the presence of A, B and
O blood group and Lewis antigens. Saliva was boiled for
10 min, and then centrifuged at 3000 g for 2 min and then at
10 000 g for 10 min to pellet debris. The saliva samples
were diluted 1000-fold in carbonate/bicarbonate buffer at pH
9.6, and incubated overnight at 37°C on an ELISA plate. On
the following day, the plates were washed three times with
PBS (pH 7.4) containing 0.05% Tween 20% (PBS-T). Non-
speciﬁc sites were blocked with 4% skimmed milk–PBS for
2 h at 37°C, and then washed three times with PBS-T. A 4%
skimmed milk–PBS solution was also used for the dilution of
primary and secondary antibodies in a ﬁnal volume of 100 μL
per well. Anti-A and anti-B mouse IgG antibodies (Diagast,
Loos, France) were diluted 5000-fold, and anti-H-speciﬁc IgM
(Thermo Fisher Scientiﬁc, Villebon sur Yvette, France) was
diluted 1000-fold. Supernatants from anti-Lewis a (clone 7LE)
and anti-Lewis b (clone 2-25LE) hybridoma supernatants
were diluted 1000-fold. 7LE and 2-25LE supernatants were
kindly provided by J. Bara. The primary antibodies were
incubated for 1 h (A, B and O blood group antigens) and
1.5 h (Lewis antigens) at 37°C. After three washes with PBS-
T, 5000-fold-diluted peroxidase-conjugated anti-mouse anti-
bodies (Vector/ABCYS, Paris, France) were incubated for
30 min at 37°C for the detection of anti-A-speciﬁc, anti-B-
speciﬁc and Lewis-speciﬁc IgG. For the detection of anti-H-
speciﬁc IgM, a 1000-fold dilution of peroxidase-conjugated
goat anti-mouse IgM antibodies (Southern Biotech/Clin-
isciences, Nanterre, France) was incubated for 45 min at 37°
C. The plates were then washed four times with PBS-T.
Peroxidase activity was detected with 100 μL of 3,30,5,50-
tetramethyl benzidine (KPL/Eurobio, Courtaboeuf, France).
The reaction was stopped after 10 min of incubation at
room temperature with 50 μL of 2 M HCl prior to reading
of the absorbance at 450 nm.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectGenotyping for the FUT2 phenotypes
The FUT2 genotype was determined in the individuals from
whom we had obtained blood samples (n = 98). DNA was
extracted from a 50-μL sample of whole blood with the
QIAamp Blood DNA extraction kit (Qiagen, Les Ulis, France),
according to the manufacturer’s recommendations. The FUT2
genotypes were determined by partial sequencing of the FUT2
gene as described previously [28].
Saliva binding assay with VLPs
For GII.3 VLP binding, a preliminary assay showed that only a
weak binding signal was obtained with 1000-fold-diluted saliva,
and 100-fold-diluted saliva was therefore used for the assay.
Five hundred nanograms of puriﬁed GII.3 VLPs was used for the
assay. Bound VLPs were detected by the use of rabbit poly-
clonal GII.3-speciﬁc serum for 1 h at 37°C. Peroxidase-
conjugated anti-rabbit antibodies were incubated for 30 min
at 37°C. Peroxidase activity was detected with 3,30,5,50-tetra-
methyl benzidine. The reaction was stopped after 20 min of
incubation at room temperature with 2 M HCl prior to reading
of the absorbance at 450 nm. Values below an optical density of
0.1 were arbitrarily considered to be negative.
Statistical analysis
StataCorp statistical software (StataCorp LP, College Station,
TX, USA) was used for the statistical analyses. To determine
whether NoV infected children at different ages, univariate
analysis was performed with the Pearson chi-square test and
Fisher’s exact test. To determine whether NoV and GII.3 NoV
infections were preferentially associated with ABO and Lewis
antigens or secretor and non-secretor genotypes, multivariate
analysis was conducted. Because of the small sample size, lo-
gistic regression models with a robust variance estimator
(Huber/White/sandwich) or exact logistic regression models
were used [29,30]. Variables with a signiﬁcance level of p <0.2
were entered into the multivariate model. The ﬁnal threshold
for signiﬁcance was set at p <0.05.ResultsEpidemiology and clinical features
One hundred and fourteen stool samples collected between
January 2011 and July 2012 were screened for the presence of
NoV. Eighty per cent of the samples were collected during the
cold season from September 2011 to March 2012 (Table S2).
Apart from one child aged 6 years, all of the children treated at
the paediatric hospital were aged <24 months, and 80% were
aged 12 months. On average, there were six diarrhoeal epi-
sodes per day at the peak of the disease. After diarrhoea, theious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e1–874.e8
TABLE 1. Distribution of norovirus genotypes according to
age group
Age (months)
Norovirus genotype
GII.1 GII.3 GII.4 GII.7
0–2 0 0 0 0
2–4 1 9 1a 1
4–6 1 4 1a 1
6–8 0 4 1b 0
8–10 2 7 0 0
10–12 0 2 0 0
12–14 0 3 1b 0
14–16 1 0 0 0
16–18 0 0 0 0
18–20 0 0 0 0
20–22 0 0 0 0
22–24 0 0 1a 0
>24 1 0 0 0
Total 6 29 5 2
aVariant 2012 GII.4.
bVariant 2010 GII.4.
CMI Ayouni et al. Norovirus and HBGA 874.e4most common symptoms were fever (n = 79), vomiting (n = 56,
mean of 4 episodes/day), and dehydration (n = 20). Dehydration
was mild (n = 8) or moderate (n = 12), with an average severity
score between 4 and 5. No cases of severe dehydration were
reported during the course of the study. NoVs were detected
in 42 specimens. Thirty-ﬁve of the 42 NoV-positive samples
were collected during the cold season (September 2011 to
March 2012). Other NoV-positive samples were collected in
January 2011 (n = 3) and March 2011 (n = 3). It is of note that
one sample from August 2012 was also positive. The average
age of infants infected with NoV was 7.8 months. Eighty per
cent of the infections occurred in infants aged <10 months.
Forty-two clinical specimens were positive for NoVs (Table 1).
GII.3 was predominant, accounting for 69% of NoV cases. GII.3
isolates were detected in children aged between 2 and 14
months. The 29 GII.3 isolates belonged to the GII.21pol ge-
notype in the polymerase region. GII.1 was the second most
common genotype, accounting for 14.3% of all NoV cases, and
was genotyped as GII.g in the polymerase region. Five GII.4
isolates were detected, and belonged to 2010 (n = 2) and 2012
variants (n = 3). GII.7 isolates were detected in two clinicalTABLE 2. Distribution of ABO blood groups, Lewis antigens and se
Lewisb
O A
+ − +
Phenotypec (n = 114) 37 1 26
Genotyped (n = 98) Se+/Se+ 6 1 8
Se+/Se− 25 0 13
Se−/Se− 0 0 0
aIndividuals were positive for the presence of A and B antigens.
bSaliva samples were phenotyped for the presence of Lewis a and b antigens.
cSaliva samples were obtained from 114 patients, and phenotyped for the presence of ABO
dAmong the 114 individuals, blood samples were collected for a subset of 98 patients. Allele
secretor; Se−/Se−, homozygous non-secretor.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inspecimens, and were genotyped as GII.21pol in the polymerase
region.
HBGA phenotype and secretor genotype
One hundred and fourteen saliva samples corresponding to the
114 faecal specimens were phenotyped by ELISA for the
presence of ABO HBGAs and Lewis antigens (Table 2). A, B
and H blood group antigens were detected in 78.9% of saliva
samples (n = 90). For 24 samples, the presence of ABH blood
group antigens was below the detection threshold. Among the
90 ABO-positive samples, 38 were O, 27 were A, 19 were B,
and six were strongly positive for A and B, which characterizes
the AB group. The Lewis antigen was detected in 109 in-
dividuals. Thirty-seven, 26 and 16 saliva samples were also
positive for the Lewis antigen in O, A and B individuals,
respectively. The six AB individuals were all positive for the
Lewis antigen. For ﬁve individuals of the O (n = 1), A (n = 1) and
B (n = 3) types, representing 4.4% of the cohort, the Lewis
antigen was not detected in the saliva samples. The strong
reactivity of these 24 samples against the Lewis a-speciﬁc
monoclonal antibody rather than against a monoclonal antibody
raised against the Lewis b antigen suggested that the 24 in-
dividuals had a non-secretor phenotype (Fig. S1). To conﬁrm
this hypothesis, the FUT2 secretor phenotype was determined
by genotyping the FUT2 gene by sequencing and partial
sequencing of the FUT2 gene for 98 patients, including 22 of 24
individuals for whom saliva samples were Lewis a positive and
ABO negative. We found that these 22 individuals, representing
22.45% of the study population, had a non-secretor genotype
and possessed the mutation G428A. None of the samples
showed the A385T mutation. For the other patients with
positive saliva test results for either A, B or H antigens, 76
blood samples were available. Genotyping conﬁrmed that they
all had a secretor genotype. Among these 76 secretors, 23
(23.47% of the study population) were homozygous (Se+/Se+)
for the FUT2 gene, whereas 53 (54.08% of the study population)
were heterozygous (Se+/Se−). The age distribution for the
HBGA phenotype is shown in Fig. S2.cretor status among the patients from the cohort
B ABa
Non-
secretors
− + − + − + −
1 16 3 6 0 24 0
0 6 0 2 0 0 0
1 8 3 3 0 0 0
0 0 0 0 0 22 0
antigens.
distribution for the FUT2 gene: Se+/Se+, homozygous secretor; Se+/Se− heterozygous
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e1–874.e8
TABLE 3. Distribution of secretor and non-secretor genotypes
among norovirus-positive patients
Secretorsa Non-secretorsa
Se+/Se+b Se+/Se−b Se−/Se−b
GII.3 5 18 5
GII.4 2 2 0
GII.7 1 0 1
GII.1 0 0 1
aSecretor and non-secretor genotypes were determined by sequencing for
the nonsense mutations A385T and G428A for 35 of 42 norovirus-positive
cases [28,40].
bAllele distribution for the FUT2 gene: Se+/Se+, homozygous secretor; Se+/Se−,
heterozygous secretor; Se−/Se−, homozygous non-secretor.
874.e5 Clinical Microbiology and Infection, Volume 21 Number 9, September 2015 CMIPresence of NoVs and the FUT2 phenotype
To determine the relationship between the secretor status and
the presence of NoV, paired faecal samples and blood samples,
in addition to saliva samples, were analysed in 35 NoV-infected
patients. The NoVs infected homozygous and heterozygous
secretor individuals equally. However, for GII.3 NoV, the ma-
jority of the infections occurred in heterozygous secretor in-
dividuals (18 of the 29 infections; Table 3).
Distribution of HBGAs in NoV-infected patients
NoVs were detected in secretor and non-secretor patients
(Table 4), and all but two of these patients were Lewis positive.
The predominant GII.3 isolates were detected in individuals
who primarily belonged to group O (n = 15), followed by in-
dividuals in group A (n = 6). GII.3 isolates were also detected in
group B and AB patients, and in non-secretors. Other NoV
genotypes were detected in group O (GII.1 and GII.4), group A
(GII.1), group B (GII.1, GII.4, and GII.7) and non-secretor
Lewis-positive patients (GII.1 and GII.7). There was no signiﬁ-
cant association between NoV polymerase and capsid genotype
and HBGA distribution.
GII.3 SW4 strain binding proﬁle of saliva
GII.3 NoV was detected in ﬁve stool samples from Lewis-
positive non-secretor patients. To further characterize NoVs
that infected non-secretor patients, the GII.3 SW4 strain was
selected from a Lewis-positive non-secretor patient for whomTABLE 4. Distribution in saliva of ABO blood groups and Lewis an
Lewis
O A B
+ − + − +
GII.3 15 0 6 0 1
GII.4 3 0 0 0 1
GII.1 3 0 1 0 1
GII.7 0 0 0 0 1
Total 21 0 7 0 4
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectwe had characterized stool, saliva and blood samples. The
complete nucleic acid sequence of the SW4 ORF2 (Genbank
KM056394) showed 98% nucleic acid identity with the GII.3
‘693/425’ paediatric strain from Australia (Genbank number
KC464328) [31]. The VLPs were puriﬁed to >90% homoge-
neity following production and concentration from insect cells.
The origin was conﬁrmed with NoV-speciﬁc polyclonal serum
(Fig. S3).
GII.3 SW4 VLPs were assayed on the 114 saliva samples
collected (Fig. 1), and were found to bind to A, B and AB Lewis-
positive saliva. The magnitude of the binding varied greatly from
person to person. No binding was observed for the Lewis-
negative O, A and B saliva (n = 5). Residual binding to no
binding was observed for O and non-secretor saliva. For the
patient who provided samples from which the GII.3 VLPs were
produced, no binding was observed with 100-fold-diluted and
ten-fold-diluted saliva (data not shown), whereas a strong
response for the presence of the Lewis a antigen was obtained
with 1000-fold-diluted saliva.DiscussionA recent report from Tunisia showed that NoV affected 7.7%
and 10.5% of non-hospitalized and hospitalized patients,
respectively, between 2007 and 2010 [32]. GII NoVs were
predominant over GI NoVs. Among GII NoVs, the GII.3 ge-
notype became predominant during the winter of 2009–2010.
Our data conﬁrm that GII.3 NoVs mostly circulate in the
paediatric population, as reviewed previously [33]. One hy-
pothesis to explain why GII.3 NoVs were associated with
paediatric cases is that the intestinal tract is mostly immature
during the ﬁrst years of life, and might provide a favourable
environment for opportunistic infection by GII.3 NoVs.
As in previous reports, we observed that NoV infection
mostly occurred in secretor individuals [12,13,34]. We
observed that GII.3 and GII.7 isolates also affected Lewis-
positive non-secretor individuals, as reported previously
[12,17,35], whereas NoV infection has never been reported in
Lewis-negative non-secretor individuals. This suggests that thetigens among norovirus-positive cases
AB Non-secretors
− + − + −
1 1 0 5 0
1 0 0 0 0
0 0 0 1 0
0 0 0 1 0
2 1 0 7 0
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e1–874.e8
CMI Ayouni et al. Norovirus and HBGA 874.e6Lewis antigen might play an essential role in NoV recognition by
intestinal cells in non-secretor individuals. Nonetheless, VLPs
from GII.3 NoV isolated from a chronically infected patient, and
called the Chron1 strain, could not bind a panel of non-secretor
saliva samples [36]. Our study allowed us to characterize and to
clone a GII.3 NoV strain isolated from a symptomatic non-
secretor Lewis-positive patient. Our ﬁrst objective was to
determine whether this strain isolated from this non-secretor
individual could bind the patient’s own saliva and saliva from
other non-secretors. As the VLPs did not bind non-secretor
saliva, including the saliva of the patient from whom the
isolate came, we formulated several hypotheses. We ﬁrst hy-
pothesized that there was no binding because HBGAs were
absent from the saliva sample. This was very unlikely, as we
observed strong binding to saliva for GII.4 VLPs (Fig. S4), and a
marked signal was observed by ELISA for the presence of Lewis
a antigen during phenotyping (Fig. S1). The second hypothesis
was that the absence of binding could be due to an artefact.
Indeed, it is possible that no binding was observed because the
VLPs were not structurally sound. However, as the GII.3 VLPsFIG. 1. Saliva binding assays for the GII.3 SW strain. The value for each sample
with GII.3 and non-GII.3 noroviruses are indicated by red and blue bars, respe
GII.3 isolate found in the stool specimens was used for baculovirus-expressed
in duplicate for each sample, and the mean values are given on the graph (optic
of the graph by minus (absence of Lewis antigen) and plus (presence of Lewis a
indicated on the abscissa, and are separated by vertical dashed lines. The thick
assay was arbitrarily considered to be negative.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Indid bind with A and B saliva from secretor individuals, we
concluded that the GII.3 VLP structure was correct. It is of note
that we successfully used SW4 GII.3 VLPs in binding experi-
ments with duodenum tissue from secretor individuals (Fig. S5),
again demonstrating that the VLP conformation was correct.
Binding for GII3 VLPs, however, was markedly lower than that
for GII.4 VLPs, as described previously [36,37] (Fig. S4). We
then hypothesized that the presence of HBGAs in saliva did not
reﬂect the ABO status at the intestinal level. This is very un-
likely, because HBGAs are present in the intestine at birth, and
persist for the ﬁrst 2 years of life [38]. Moreover, Lewis, A and
H antigen expression is complete in saliva at birth for term
infants, whereas it is delayed in red blood cells [39]. Finally, in
the event that the Lewis antigen does not participate in the
attachment of NoV for non-secretor individuals, we hypothe-
sized that non-HBGA ligands or precursor carbohydrates could
constitute an alternative attachment pathway for NoVs during
the ﬁrst months of life.
Our data suggested that the HBGAs present in the saliva
from young non-secretor individuals did not reﬂect the bindingis represented by a bar on the graph. Binding values for patients infected
ctively. An arrow indicates the binding value of the patient for whom the
virus-like particle production. The binding experiments were performed
al density (OD)450 nm; ordinate). The Lewis status is indicated at the top
ntigen) signs. The non-secretor and human blood group antigens are also
horizontal dashed line indicates the threshold below which the binding
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e1–874.e8
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ligand might play a role during NoV infection. A recent study
provided evidence of this, by showing that previous infections
with CagA-positive H. pylori might interfere with HBGA
expression [18]. Infection with H. pylori is, however, very un-
likely in the ﬁrst years of life. Nonetheless, immature
carbohydrate-like type 1 chain precursors and non-HBGA li-
gands might contribute to the increased susceptibility of a large
proportion of children to NoV infections. Recent ﬁndings have
also suggested that certain bacteria (e.g. E. cloacae) from the
microbiota might participate in NoV infection [19]. These
ﬁndings support the notion that genetic and microbiological
factors are at play during NoV infection. Synergistic and
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